Background:  Cell cycle progression is regulated by a series of cyclin-dependent kinases that consist of catalytic subunits designated Cdks and activating subunits designated cyclins. Orderly progression through the cell cycle requires the activation and inactivation of different cyclin-Cdks at appropriate times. A series of proteins has been described that function as mitotic inhibitors. These include p21, the levels of which are elevated upon DNA damage in G1 in a p53-dependent manner; p16; and p16-related inhibitors, designated p15, p18 and p19. A p21-related protein, p27, has been described as a negative regulator of G1 progression and has been speculated to function as a possible mediator of TGF b-induced G1 arrest. A member of the p21/p27 family of mitotic inhibitory proteins, p57 (also designated Kip2), is a potent, tight-binding cyclin-dependent inhibitor of several G1 cyclin/Cdk complexes. Overexpression of p57 arrests cells in G1. Unlike p21, p57 is not regulated by p53.

Description: Rabbit polyclonal to p57

Immunogen: KLH conjugated synthetic peptide derived from p57

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 35 kDa;

·Immunohistochemistry (Frozen/paraffin tissue section): 1/50-200;

·Immunocytochemistry: 1/100;

·ELISA: 1/1000;

·Optimal working dilutions must be determined by the end user.